# A Phase Ia/Ib, SAD and MAD Study of of KL1333 in Healthy Subjects and Patients With Primary Mitochondrial Disease

> **NCT03888716** · PHASE1 · COMPLETED · sponsor: **Abliva AB** · enrollment: 72 (actual)

## Conditions studied

- Mitochondrial Diseases
- Mitochondrial Respiratory Chain Deficiencies
- MELAS Syndrome
- Mitochondrial Myopathies

## Interventions

- **DRUG:** KL1333
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT03888716
- **Lead sponsor:** Abliva AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-18
- **Primary completion:** 2021-03-16
- **Final completion:** 2021-03-16
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2021-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03888716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03888716, "A Phase Ia/Ib, SAD and MAD Study of of KL1333 in Healthy Subjects and Patients With Primary Mitochondrial Disease". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03888716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*